iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company headquartered in Singapore, has recently made significant strides in its pursuit of emergency use approval for its sublingual ketamine wafer, Wafermine. This product is currently under phase 2 clinical trials for the management of moderate to severe pain and is being considered for battlefield pain management applications. The company’s announcement marks a pivotal moment, as it progresses toward an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).
The U.S. government has facilitated a rare emergency regulatory pathway, allowing iX Biopharma to submit an EUA request later this year. This development is particularly noteworthy as it could enable the drug to reach U.S. military personnel ahead of full FDA clearance. Such a move would not only provide early revenue streams for the company but also support ongoing phase-three trials. The chairman of iX Biopharma emphasized the significance of this government declaration, noting that such pathways are uncommon and represent a substantial opportunity for the company.
This advancement follows a recent contract from the U.S. government, which will fund part of the drug’s development and regulatory efforts. The announcement was significant enough to prompt a brief trading halt, which was lifted before the market opened on September 7, 2026. As of that date, the company’s close price was SGD 0.54, with a 52-week high of SGD 0.585 and a low of SGD 0.019. The market capitalization stands at SGD 628,656,384, despite a negative price-to-earnings ratio of -65.221.
iX Biopharma operates through three primary segments: Specialty Pharmaceutical, Chemical Analysis, and Nutraceutical. In addition to Wafermine, the company’s product portfolio includes BnoX, a sublingual buprenorphine wafer for moderate to severe pain; Wafesil, a sublingual sildenafil wafer for male erectile dysfunction; and Silcap, another product for the same indication. The company also promotes and markets nutritional and supplement products through pharmacies and online channels, while developing and commercializing nutraceutical products. Furthermore, iX Biopharma provides laboratory services, enhancing its comprehensive approach to healthcare solutions.
Founded in 2008, iX Biopharma has established a strong presence in Australia, Singapore, and Malaysia. The company’s strategic focus on innovative pain management therapies and its ability to navigate complex regulatory environments underscore its potential for growth and impact in the healthcare sector. As it moves forward with its EUA request, iX Biopharma continues to position itself as a key player in the specialty pharmaceutical and nutraceutical markets.
